University of South Florida

Vijaykumar Bhadabhai Sutariya

Yashwant V Pathak

Umesh Kumar Jinwal

Srinivas M Tipparaju

Kathleen Emily-Ann Halasz

Priyanka Sureshbhai Bhatt

Anjali A Hirani

Vipul B Amin

Javier Cuevas

Ramesh Ayyala

Manas Biswal

Kevin Sneed

Radouil Tzekov

Christopher Katnik

Disclosed are nanoparticles and nanogel drug compositions and the use thereof for treating age-related macular degeneration.

Nanoparticles and nanogel drug compositions for treatment of age-related macular degeneration

The present disclosure provides for an ophthalmological composition comprising remdesivir and an ophthalmologically suitable carrier, and the use thereof for treating and preventing a coronavirus infection and treating conjunctivitis.

Ophthalmological formulations for the prevention of a coronavirus infection

The present invention concerns nanoparticles useful for treating posterior segment ocular diseases or conditions, such as macular degeneration and diabetic retinopathy; compositions comprising the nanoparticles; methods for producing the nanoparticles; and methods for treating posterior segment ocular diseases or conditions, comprising administering the nanoparticles or compositions to the ocular posterior segment of an afflicted eye.

Nanoparticles for treatment of posterior segment ocular diseases and conditions

Nanoparticle based MKT formulation. MKT is encapsulated by poly(ethylene glycol)ylated (PEGylated) poly-(lactide-co-glycolide) (PLGA) to form nanoparticles (NPs). To induce trans-BBB permeability, glutathione (GSH) is coated on the resulting NPs. Newly generated MKT-NPs showed BBB permeability and tau reduction in experimental models. Specifically, brain-targeting MKT NPs were developed with a glutathione coating, characterized, and shown to permeate BBB permeation insert models as a therapeutic for Alzheimer's disease and related tauopathies.

Glutathione-coated nanoparticles for delivery of MKT-077 across the blood-brain barrier

The present invention provides a sustained drug delivery system for the treatment of age-related macular degeneration (AMD), comprising corticosteroid encapsulated nanoparticles incorporated into a thermoreversible hydrogel. The corticosteroid may be triamcinolone acetate (TA), dexamethasone, or loteprednol etabonate (LE). The proposed drug delivery system is nontoxic to ARPE-19 (retinal pigment epithelium) cells and significantly reduces VEGF (vascular endothelial growth factor) expression as compared to solutions of the coticosteroids. The present invention provides sustained delivery of the corticosteroid to the posterior segment of the eye, reducing the frequency of intraocular injections necessary to maintain therapeutic concentrations.

Loteprednol etabonate nanoparticles in thermoreversible gels for enhanced therapeutics

A delivery system of coated and uncoated nanoparticles (NP) for delivery of methylene blue (MB). The delivery system was developed using PLGA-based polymer that was repeatedly shown to be biocompatible and biodegradable. The parameters of synthesized NPs were within the suitable range for BBB permeation&#x2014;specifically, the NPs were monodispersed, with slight negative charge, and with the size within 100-150 nm range suitable for intravenous delivery and delivery to the brain. The coating on the nanoparticle did not have a significant impact on the nanoparticle size and zeta potential. Based on the immunoblotting experiments using AD cellular model, the GSH coated NPs were better in reducing tau levels compared to MB solution. In vitro BBB Transwell permeation study showed eight fold higher MB-NP permeation compared to the MB solution over 24 hours.

Preparation and characterization of methylene blue nanoparticles for Alzheimer's disease and other tauopathies

Nanoparticles in thermoreversible gels for enhanced therapeutics

A novel nanoparticle drug composition and method of use thereof is presented herein. The nanoparticle drug composition is comprised of at least one nanoparticle carrier, formed from the conjugation of PLGA and PEG, which encapsulates a drug such as afobazole and its derivatives, in a pharmaceutically acceptable carrier. The nanoparticle drug composition may be used to treat various diseases of the central nervous system involving excessive neuronal activity and inflammation such as stroke, Alzheimer's disease and anxiety.

Growing community of inventors

Tampa, FL, United States of America

Vijaykumar Bhadabhai Sutariya